GlobeNewswire

myToys Delivers Oracle e-Business Suite Projects Faster Using Delphix Dynamic Data Platform

Dela

Top European family shopping retailer selects Delphix to reduce time-to-market, improve software quality, offer faster disaster recovery, accelerate financial close and reduce costs

FRANKFURT, Germany and REDWOOD CITY, Calif., Oct.  25, 2017  (GLOBE NEWSWIRE) -- Delphix, the company that has changed the dynamics of managing and consuming data, today announced top online retailer myToys has selected the Delphix Dynamic Data Platform to support their Oracle E-Business Suite (EBS) projects and drive continuous innovation.

myToys uses Oracle EBS to run everything from purchasing, finance and accounting to order/ inventory management, customer service and logistics. By adopting the Delphix Dynamic Data Platform, myToys expects to use secure, up-to-date data to improve application development and testing processes, reduce time-to-market and improve quality.

myToys ERP embraces DevOps in many aspects of the Software Development Life Cycle, the goal of which is to strive for daily application releases that keep up with market changes; however, they found that their test automation processes were broken and inhibited both quality and speed. Before the Delphix implementation, their development team shared two environments between them to support the 70+ projects they worked on per quarter, which inhibited the development process and stifled innovation.

"With Delphix, our vision is to let any developer generate an environment on-demand risk-free with the right data and application stack. Data operators will be able to provide self-service access to developers, accelerating the speed at which they can work on critical projects," stated Ralf Schmilewski, head of ERP Development with myToys.

After evaluating potential solutions, myToys selected Delphix, as the team found the platform to be a proven solution for Oracle EBS projects. Other important factors in the decision were the mature DevOps features in the Delphix Dynamic Data Platform and ease of implementation resulting in rapid time-to-value.

Schmilewski continued, "Delphix has many Oracle EBS customers around the world and demonstrated a wealth of expertise and knowledge in their German team. We felt confident in the best practices and data expertise by the Delphix technical staff. In addition, Delphix self-service features are built for test automation. Delphix is the missing link in DevOps."

With data forecasted to grow at 20% per year, myToys is also expecting a considerable storage savings due to the way Delphix virtualizes at the data level.

"We are delighted that myToys has chosen Delphix and recognizes the value the Delphix Dynamic Data Platform will deliver to their Oracle EBS projects," explained Minas Botzoglou, Regional Sales Manager for DACH at Delphix. "We look forward to helping more companies in Europe and across the world maximize the effectiveness of DevOps investments to drive innovation."

For more information on the Delphix Dynamic Data Platform, please visit:

·        Platform Solution Brief
·        Link to the Cloud Release

About Delphix

Delphix's mission is to free companies from data friction and accelerate innovation. Fortune 100 companies use the Delphix Dynamic Data Platform to connect, virtualize, secure and manage data in the cloud and in on-premise environments. For more information visit www.delphix.com

About the MYTOYS GROUP

The MYTOYS GROUP - with headquarters in Berlin and part of the Otto Group - is one of Germany's most successful E-Commerce companies for the target group of families and women. Since 1999, the MYTOYS GROUP operates under the brand myToys Germany's leading online shop and retailer for toy, leisure product and baby care and 16 retail stores trading under the same name. myToys is the leading Multi-Channel-Provider for children's products in German speaking countries. In 2010, the women's fashion online store ambellis was launched, which also belongs to the MYTOYS GROUP. Since 2013, the online shoe shop mirapodo and the shopping community limango also belong to the MYTOYS GROUP family. With the innovative combined shopping concept, customers are able to purchase simultaneously in the online shops myToys, ambellis and mirapodo. With just one account and a shared shopping cart, the online shopping experience is easy and convenient. The MYTOYS GROUP currently employs more than 2,000 employees. Sales revenue amounted to over 500 million euros in the fiscal year 2015/16.

CONTACT:

Alex Plant / alex.plant@delphix.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Delphix via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum